Marker Therapeutics Inc (MRKR)
Marker Therapeutics Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker MRKR. The company focuses on immuno-oncology, with work centered on T cell-based approaches for cancers, including hematological malignancies and solid tumors in the United States. Its MAR-T platform is designed to expand tumor-specific, non-engineered T cells that can recognize cancer-related antigens and target cells carrying those markers. The pipeline includes MT-601, which is being studied in Phase 1 trials for lymphoma and pancreatic cancer, and MT-401-OTS, a Phase 1 candidate being evaluated in acute myeloid leukemia and myelodysplastic syndromes. The company was founded in 1999 and is headquartered in Houston, Texas. It was previously known as TapImmune, Inc. before adopting its current name in October 2018.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MRKR
|
$2.19
|
67.5% Upside
|
Bargain
|
$7.87
|
500.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-2.0x
|
1.6x
|
6.2x
|
21.342 M
|
6.926 M
|
0.0%
|
82.4%
|
-34.7
|
—
|
72.7%
|
